Kardigan KARD

Kardigan, Inc. is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. The company focuses on creating new standards of care for high-need patients through its pipeline of late-stage programs designed to address genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension. Its mission is to advance multiple targeted cardiovascular treatments in parallel that bring patients closer to the cures they deserve.

Kardigan generates revenue through the development and potential commercialization of its proprietary therapeutic candidates, including Danicamtiv, Ataciguat, and Tonlamarsen, which are designed to treat specific cardiovascular indications with significant unmet need. The company does not currently have approved products on the market and relies on future regulatory approvals and potential sales of its pipeline candidates to generate revenue. Its general customer base includes patients, healthcare providers, and healthcare systems seeking innovative treatments for underserved cardiovascular conditions.

The company operates through the following segments:

• Danicamtiv: This segment focuses on the development of an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy. Danicamtiv targets sarcomeric defects in patients with primary abnormalities in the thick filament or cardiac myosin, including pathogenic variants in the MYH7 and TTN genes. The program is currently being evaluated in the KINSHIP-DCM Phase 2b/3 trial, with topline data from the Phase 2b portion expected in the first half of 2027.
• Ataciguat: This segment develops an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate disease. Ataciguat targets valvular interstitial cells to slow osteogenic and calcific remodeling, the underlying driver of disease progression. The program is being evaluated in the KATALYST-AV Phase 2b trial, with interim data anticipated in the first half of 2027, followed by a Phase 3 registrational trial.
• Tonlamarsen: This segment advances an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection for the management of blood pressure in acute severe hypertension patients post-hospitalization. Tonlamarsen targets hepatic angiotensinogen to enable consistent and sustained blood pressure management during the post-hospitalization transition period. The program is currently being evaluated in the KARDINAL-ASH Phase 2 trial, with topline data expected in the first half of 2027.

Kardigan positions itself as a leader in precision cardiovascular therapeutics through its proprietary Cardiac Intelligence toolkit and Prolaio platform, which integrate real-world data collection and advanced analytics to improve clinical trial efficiency and success rates. The company differentiates itself by targeting root causes of disease rather than symptoms, with a focus on genetically defined patient populations and innovative trial designs that reduce enrollment size and duration. Its management team, composed of veterans from MyoKardia, brings deep expertise in cardiovascular drug development and a proven ability to navigate complex regulatory and clinical pathways.

Kardigan serves patients with high unmet medical needs in specific cardiovascular indications, including those with genetic dilated cardiomyopathy, moderate calcific aortic valve stenosis, and acute severe hypertension following hospitalization. The company also engages with healthcare providers, clinical trial investigators, and healthcare systems involved in the diagnosis, treatment, and management of these cardiovascular conditions. Its therapeutic candidates are designed for use in outpatient and inpatient settings, with a focus on improving transitions of care and reducing hospital readmissions and mortality in vulnerable patient populations.